logo

Biohaven Pharmaceutical Holding Co Ltd. (BHVN)



Trade BHVN now with
  Date
  Headline
6/17/2021 4:05:58 PM Biohaven Appoints Kishen Mehta To Board Of Directors
5/10/2021 8:11:25 AM Biohaven Pharmaceutical Q1 Net Loss $261.0 Mln Vs. Net Loss $172.9 Mln Last Year
4/13/2021 7:34:48 AM Biohaven Pharma Highlights Neuroscience Advancements With 22 Presentations
4/7/2021 7:35:54 AM Biohaven Reports $43.8 Mln In Net Product Revenue From Sales Of NURTEC ODT In Q1
3/29/2021 7:33:29 AM Biohaven Enrolls First Patient In Phase 2/3 Trial Of Oral Zavegepant For The Preventive Treatment Of Migraine
3/15/2021 10:48:19 PM Biohaven Prices Underwritten Public Offering Of 2.69 Mln Shares At $76.00/shr
3/11/2021 7:47:38 AM Biohaven: NURTEC ODT Approved By United Arab Emirates Ministry Of Health And Prevention For Acute Treatment Of Migraine
3/10/2021 7:33:41 AM Biohaven And Medison Pharma: NURTEC ODT Approved By Israeli Ministry Of Health For Acute Treatment Of Migraine
3/1/2021 7:45:22 AM Biohaven Q4 Adj. Net Loss $161.7 Mln Or $2.69/shr Vs. Loss $124.4 Mln Or $2.38/shr Prior Year
2/22/2021 7:36:32 AM Biohaven's Multimodal Antibody Therapy Enhancer BHV-1200 Shows Effective Neutralization Of Multiple Strains Of COVID-19
1/25/2021 7:41:58 AM Biohaven Reports $35 Mln In Net Product Revenue From Sales Of NURTEC ODT In Q4, Represents 98% Increase Prior Quarter
1/7/2021 7:45:30 AM Biohaven Announces Acquisition Of Remaining 58% Interest Of Kleo Pharmaceuticals
1/4/2021 7:34:22 AM Biohaven Commences Enrollment In Phase 3 Clinical Trial Assessing Efficacy And Safety Of Troriluzole
12/16/2020 7:32:33 AM Biohaven Says The Lancet Published Positive Results From A Phase 3 Clinical Trial Of Rimegepant
11/9/2020 8:11:07 AM Biohaven Q3 Loss/shr $3.27 Vs. Loss/shr $2.04 Last Year
10/14/2020 7:32:49 AM FDA Accepts Biohaven's SNDA Of NURTEC ODT For Preventive Treatment Of Migraine